Evidence-Based Guidance on New Paradigms in the Treatment of Acute Myeloid Leukemia
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Prostate Cancer in Black Individuals: How Can We Do Better?
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.
Category
  • Prostate Cancer
Format
  • Enduring Activity
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Diagnosis and Management of Breast Cancer: What does the Evidence Show, What are We Doing, And What’s on the Horizon?
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast cancer in Black patients.
Category
  • Breast Cancer
Format
  • Enduring Activity
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments
Ampullary adenocarcinoma is frequently grouped with biliary tract and pancreatic cancers due to its low prevalence. Because of its rarity, it is not a well-known or studied cancer in the community. Systemic therapies used to treat ampullary adenocarcinoma are complex and pharmacists play an important role in managing treatment, toxicity, and supportive care measures.
Category
  • Ampullary Adenocarcinoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Category
  • Thyroid Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date September 25, 2023
Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
  • Kidney Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date October 17, 2023
Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix
The management of cervical cancer specific to histology, stage, and setting has changed tremendously and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.
Category
  • Cervical Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date November 30, 2023
Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date December 6, 2023

Pages